Document Detail


Tankyrase-targeted therapeutics: expanding opportunities in the PARP family.
MedLine Citation:
PMID:  23197039     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
The poly(ADP-ribose) polymerase (PARP) protein superfamily has wide-ranging roles in cellular processes such as DNA repair and WNT signalling. Efforts to pharmacologically target PARP enzymes have largely focused on PARP1 and the closely related PARP2, but recent work highlighting the role of another family member, tankyrase 1 (TANK1; also known as PARP5A and ARTD5), in the control of WNT signalling has fuelled interest in the development of additional inhibitors to target this enzyme class. Tankyrase function is also implicated in other processes such as the regulation of telomere length, lung fibrogenesis and myelination, suggesting that tankyrase inhibitors could have broad clinical utility. Here, we discuss the biology of tankyrases and the discovery of tankyrase-specific inhibitors. We also consider the challenges that lie ahead for the clinical development of PARP family inhibitors in general.
Authors:
Jenna L Riffell; Christopher J Lord; Alan Ashworth
Related Documents :
6769899 - Properties of beta-galactosidase iii: implications for entry of galactosides into klebs...
16128589 - Ground-state, transition-state, and metal-cation effects of the 2-hydroxyl group on bet...
20714719 - A new α-galactosidase from symbiotic flavobacterium sp. tn17 reveals four residues ess...
7418839 - Influence of sex, developmental time and food on beta-n-acetylglucosaminidase activity ...
8424679 - Structural and functional studies on the interaction of sodium dodecyl sulfate with bet...
11754559 - Composition and seasonal variation of the essential oil from leaves and peel of a creta...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Nature reviews. Drug discovery     Volume:  11     ISSN:  1474-1784     ISO Abbreviation:  Nat Rev Drug Discov     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101124171     Medline TA:  Nat Rev Drug Discov     Country:  England    
Other Details:
Languages:  eng     Pagination:  923-36     Citation Subset:  IM    
Affiliation:
The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Fulham Road, London SW3 6JB, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Reducing safety-related drug attrition: the use of in vitro pharmacological profiling.
Next Document:  Protein kinase C, an elusive therapeutic target?